Southpoint Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Southpoint Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-600,000	Closed	-$111M	–	45
2024 Q4	$111M	Sell	600,000 -69,976	-10%	-$13.5M	2.6%	21
2024 Q3	$132M	Sell	669,976 -480,024	-42%	-$99.8M	3.13%	11
2024 Q2	$238M	Buy	1,150,000 +450,000	+64%	+$102M	5.91%	3
2024 Q1	$190M	Sell	700,000 -300,000	-30%	-$71.6M	3.75%	9
2023 Q4	$236M	Buy	1,000,000 +200,000	+25%	+$39.3M	5.08%	4
2023 Q3	$157M	Buy	800,000 +400,000	+100%	+$82.1M	3.5%	11
2023 Q2	$84.1M	Hold	400,000	–	–	1.82%	22
2023 Q1	$80.7M	Buy	+400,000	New	+$90.7M	1.83%	21
2022 Q4	–	Sell	-500,000	Closed	-$98.4M	–	55
2022 Q3	$98.4M	Buy	500,000 +100,000	+25%	+$21.6M	2.65%	15
2022 Q2	$85.6M	Buy	+400,000	New	+$97.7M	2.43%	17

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Southpoint Capital Advisors's CRL Position: Q1 2025 in Review

Southpoint Capital Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 600,000 shares — an estimated $111M sold.

Southpoint Capital Advisors first reported a position in CRL in Q2 2022 and held it in 10 quarters. The position peaked at $238M in Q2 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Southpoint Capital Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Southpoint Capital Advisors sold 600,000 Charles River Laboratories shares in Q1 2025, an estimated $111M.
Southpoint Capital Advisors first reported a position in Charles River Laboratories in Q2 2022 and held it in 10 quarters.
Southpoint Capital Advisors's Charles River Laboratories position peaked at $238M in Q2 2024.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Southpoint Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.